The present invention relates to methods and an apparatus for the in-vivo optical measurement of blood chemistry, and in particular the oxygenation of red blood cells.
Prior art methods of measuring the oxygenation of blood are well known and utilize various means to measure light absorption at specific wavelengths in the Near Infrared (NIR) of the spectrum of electromagnetic radiation to distinguish between the concentration of the oxygenated hemoglobin and de-oxygenated or reduced hemoglobin in red blood cells (RBC's). Externally worn sensors, typically deployed on a finger of other thin external appendage, are widely deployed but give a gross average of the oxygenation of RBC's in the large number of veins and artery that are illuminated by an external light source. Of more interest to researchers and clinicians are local arterial measurements at a specific location.
U.S. Pat. No. 5,280,786 to Wlodarczyk et al. issued on Jan. 25, 1994 for an Fiberoptic blood pressure and oxygenation sensor deployed on a catheter placed transcutaneously into a blood vessel. A sensing tip of the catheter includes a pressure-sensing element and an oxygen saturation-measuring element. One of the disclosed means for measuring the oxygen saturation of blood was a sensing tip comprising an optical fiber having at least a portion of the cladding removed. Other features of this invention included novel tip designs, measuring head features, and approaches for enhancing measurement though correlation of the saturation and pressure readings.
While the device disclosed in the '786 patent was an improvement of the prior art in providing a means to measure oxygenation in a single vein or artery it appears to still suffer several limitations of potential consequence to more extensive an long term clinical deployment in patents.
One limitation recognized by the inventors in the current invention is that the geometry created by the removal of the fiber cladding and to enable the other features is that it creates an irregular protruding device in the blood stream. As such, a device is placed in smaller arteries and veins, where the flow velocity is higher; there is a greater likelihood that the protrusion will result in turbulent blood flow that can disrupt RBC's leading to hemolysis.
For such reasons, and others it would be desirable to have a fiber optic sensor such as that disclosed in the '786 patent that is at least one of more sensitive and smaller in size, and preferably both and does not suffer from the disadvantages of prior art.
It is therefore a first object of the present invention to provide an optical means for precise local measurement of oxygenated hemoglobin and reduced hemoglobin that can potentially be smaller than the size provided by the prior art.
It is a further objective of the present invention to provide an optical sensing means that is sufficiently compatible with blood that it can remain in a patient for a long period of time, and be deployed in smaller veins and/or arteries.
It is yet another object of the present invention to provide such a sensor device that is easier to integrate with other biomedical devices and transducers
It is also a further objective of the present invention to provide such a device that is capable of a far more accurate local and representative determination of concentrations of in-vivo blood components, including oxygenated hemoglobin and reduced hemoglobin.
In the present invention, the first object of having a reduced size device that is non-protruding is achieved by providing in optical communication a laser or other light source, a beam splitter and a first detector to receive a portion of the energy directed to it by the beam splitter. The other portion of the energy directed by a beam splitter is transported to a planar waveguide in contact with the blood. Light from the laser or other source may be delivered to the planar waveguide by an optical fiber. The light attenuated by absorption of the evanescent wave in the planar waveguide is directed to a second detector. When the light is delivered by an optical fiber, the light direction means is preferably a mirror at the end of the optical fiber.
A second object of the invention of providing higher sensitivity and more representative measurement of the local concentration of oxygenated and reduced hemoglobin is achieved by providing either a planar or an optical fiber waveguide sensing device in contact with the blood wherein the refractive index of the core of the waveguide is preferably less than about 1.47. The refractive index of the waveguide core exposed to the blood is more preferably between about 1.38-1.42, the refractive index of the human RBC's, to allow the evanescent light to penetrate deeply into more RBC's than prior art devices.
The above and other objects, effects, features, and advantages of the present invention will become more apparent from the following description of the embodiments thereof taken in conjunction with the accompanying drawings.
Referring to
Before providing details on the construction and methods of using the various embodiments of the invention, theoretical consideration regarding the operative principles of such device will be described.
A step index optical fiber/dielectric waveguide has, basically, two regions with different refractive indexes: core and cladding. The core has a refractive index larger than the cladding region surrounding it. Light waves are guided throughout the waveguide due to a phenomenon known as total internal reflection. Remarkably, that propagating field is not spatially limited only to the core, but also extends into the cladding and exponentially decays with the distance from the core. This exponentially decaying field is known as an evanescent field. The extension of the evanescent field depends on the core diameter and the refractive indexes of the core and the cladding.
The absorption coefficient of silicate glass is very small in the visible and infrared ranges of the spectrum; because of that, the light absorption in the waveguide is usually neglected in the analysis of guiding modes. In contrast to the textbook analysis, in the treatment below, we consider a waveguide with a transparent core and an absorbing cladding media.
The propagation of light within dielectric medium is governed by the Helmholtz equation:
ΔE+n2k02E=0 (1)
where E=E(x, y, z) is the electric field, n is the refractive index and k0=ω/c=2π/λ is a free-space light wavevector.
The Helmholtz equation remains valid also in the case of an absorbing medium. In that case the refractive index is a complex quantity:
n=n′+in″ (2)
where n″ describes light absorption:
α=2k0n″ (3)
where α is the absorption coefficient.
For the sake of simplicity, we consider only a symmetric planar dielectric waveguide 10 as schematically illustrated in
We consider only the case of the transverse electric field. The case of the transverse magnetic field could be treated in the analogously. Seeking the solution of the Eq. (1) in the form E(x, y, z)=ŷEy(x)exp(iβz), we obtain the following equations for the propagating field
where β is the propagation constant, nj, j={1, 2} is the refractive indexes of the core and the cladding respectively. Since the refractive index of cladding is a complex quantity the same is also true for β:
β=β′+iβ″. (5)
The imaginary part of β is responsible for decaying of the propagating wave. The intensity of the wave after propagation of a distance L is:
I=I0 exp(−2β″L), (6)
where I0 is the input intensity. This intensity could be measured by a photodetector. Our goal is to relate β″ with the absorption coefficient of the cladding medium α=2k0n2″. Alternatively, defining the effective refractive index neff as
β=k0neff, (7)
the above problem could be reformulated as finding a relation between n2″ and neff″. The general solution of the Eqs. (2) has the form
Ey1=A exp(ik1x)+B exp(−ik1x)
Ey2=C exp(−γx) (8)
where Ey1, Ey2 are the fields in the core and the cladding respectively and k1 and γ are the complex numbers given by
k1=√{square root over (n12k02−β2)}
γ=√{square root over (β2−n22k02)} (9)
Ey2 is the evanescent field. It extends into the cladding on the effective distance 1/Re[γ]. The constants k1 and γ are calculated from continuity conditions of the field and its derivatives on the interface. Specifically, for the even modes: Ey(x)=Ey(−x), the following equation holds:
kt tan(k1a)=γ (10)
wherein for the odd modes: Ey(x)=−Ey(−x) the following equation holds:
k1 cot(k1a)=−γ (11)
where a =d/2 is the half of the core thickness. From Eqs (9) follows:
k12+γ2=k02NA2, (12)
where NA is the numerical aperture of the waveguide NA=√{square root over (n12−n22)}. The transcendental equations Eqs. (10)-(11) together with Eq. 12 solve the above problem. The complex propagation constant β is calculated from Eqs (9):
β=√{square root over (n12k02−k12)}=√{square root over (n22k02+γ2)} (13)
If there is no absorption, then all quantities in Eqs. (9)-(13) are real numbers. In that case, the above equations coincide with the classical equations for modal dispersion in a planar symmetric dielectric waveguide. However, when the propagating medium is absorbing, the same equations solve the problem of finding dependence of the mode intensity decay rate 2β″ on the absorption coefficient of the cladding medium α.
The dependence of the decaying rate 2β″=2k0neff″ inside the dielectric waveguide in the example above on the absorption coefficient of cladding medium α=2k0n2″ is shown on the
The dependence of γ′ on n2″ is shown on the
The main constituents of blood which contribute towards absorption in visible and near infrared ranges are water and hemoglobin. While the former is constant, the concentrations of oxygenated hemoglobin (HbO2) and reduced hemoglobin (Hb) change. Thus, the corresponding changes in absorption can provide clinically useful physiological information.
where k=log10(e)=0.4343 is a constant and c is the concentration of the compound (in units of mmoles).
In accordance with a first embodiment of the invention, an oximeter device 100 for measuring concentrations of oxygenated or oxyhemoglobin (HbO2) and reduced hemoglobin (Hb) is shown on
Light from a laser source 105 is coupled into a 50/50 2×2 fiber optic beamsplitter 115. Half of the light energy is coupled into an optical fiber 110 that ends with the oximetry probe 120 while the other half is measured on the detector D2 (122) which measures a reference signal.
In the optical fiber 110 the light propagates without losses until it enters the planar waveguide portion 130 exposed to the blood. Light enters planar waveguide portion 130 from fiber core 109 via a coupler 140, as shown by the solid arrows. In this region, the intensity of the wave exponentially decreases with the propagating distance due to interaction of the wave with the absorbing medium (blood) via its evanescent field. When the waves reach the end of the planar waveguide 130 or the fiber 120 they are reflected from the mirror on the fiber's end, as shown by the dashed arrows. An optical fiber 110 is the preferred means for delivery light from the laser source 105, as it can be readily adapted to fit into or form a catheter that is inserted into the body, and in particular the cardiovascular system. As an alternative to using coupler 140 to direct a portion of the light from optical fiber 110 to planar waveguide 130, optical fiber 110 may simply terminate in a planar waveguide having a mirror on the end face, or other means to return light back in the direction of the optical fiber indicated by the dashed arrows. It is also preferable that the light transmitted through the internal fiber but not coupled into the planar waveguide should be absorbed, rather than reflected by the mirror 150. Thus, it is more preferable that only the planar waveguide terminates in a mirror, with the end of the fiber optic terminating in an absorbing layer 180 or alternative structure or optical path that does not allow uncoupled light to reflect back to the detector.
Although the preferred embodiment deploys a mirror at the end of the fiber optic 110 used to deliver light to the planar waveguide 130, alternative embodiments include using a continuous optical fiber in the form of a loop that terminates at detector D2 (122) wherein a second optical coupler would transmit light from the planar waveguide in the same direction as propagation such that it reaches detector D2.
It should also be appreciated that rather than using a laser, a multi-wavelength light source might be deployed such as a broadband light source of multiple fiber optic lasers each tuned to a different wavelength.
The backreflected wave is transmitted through the exposed region and finally, after splitting on the beamsplitter 115 reaches the detector D1 (121). The light intensity decay in one pass of the exposed region is:
I=I0 exp(−2β″ L), (15)
where β″ is the imaginary part of β in the Eq. (13) and L is the length of the exposed region. If the transmission losses of the optical fiber and losses on the mirror and beamsplitter are negligible in comparison with the losses in the exposed region, then the following equation holds:
exp(−4β″ L)=2I1/I2 (16)
where I1, I2 are the signals on detectors D1 and D2 respectively. The factor 4 in the exponent in Eq.(16) appeared because the double pass of the exposed region. From Eq. (16) the characteristic distance L0 of the exposed region is:
At this distance the intensity decreases e times in a double pass. Although a more precise model should account for reflections at the interfaces between the cladding of the optical fiber and absorbing medium (blood) as well the losses due to fiber mode transformation when the mode field enters into the exposed region, we expect comparable trends to those shown herein.
The β″ can be expressed through the absorption coefficient of blood α by the solution of the modal dispersion equations.
The absorption coefficient of the blood depends on the concentrations of oxygenated and deoxygenated hemoglobin in it. The total absorption coefficient in the blood is a sum of specific absorption coefficients:
α=α0+αHb+αHbO
where αHbO
where cHb, cHbO
where λi {i=1, . . . , N} are wavelengths of the light. If the function α0(λ) is known, then the system of Eqs. (20) could be solved for concentrations of the Hb and HbO2. This system is over determined for N>2; it has a single solution at N=2 if the determinate of the system is not zero. If N=1, then the system is under determined and could not be solved. However, if the total concentration of hemoglobin c in blood is known, then using the additional equation:
cHb+cHbO
The concentrations cHb, cHbO
To better appreciate certain aspects and embodiments of the present invention we first illustrate the optimum and effective operative parameter for measuring blood oxygenation with a fiber optic sensor operating at the single wavelength λ=600 nm. That is, rather than utilizing the coupler and dielectric waveguide shown in
We now consider in more detail the particular advantages of the embodiment of the invention utilizing a planar dielectric waveguide 130 shown in device 100 of
Applying Eq. 16 and 17, this corresponds to the β″=0.2 cm−1 and to the effective waveguide length L=1.25 cm, which is about a third less than the optimum length (4 cm) of the exposed region for a circular optical fiber. Thus, deployment of the planar waveguide permits the portion exposed to the blood to be less than 3.5 cm.
Another important advantage of the novel planar geometry sensor compared with the prior art disclosure of optical fiber sensors is the much lower potential for error in blood saturation measurement. Sources of potential errors include variations of the optical signal of the laser and inside the optical fiber and photodetector noises. This can be modeled by letting x=cHbO
where Δμ=μHbO
The error in the determination of the saturation level from the intensities I1, I2 is from Eq. (16) and Eq. (23)
where ξ=δI1/I1−δI2/I2 is the difference of intensity variations on the two photodetectors.
From Eq. (24) we see that δx becomes smaller with the increase of Δμ, L and Γ. In the equation above Δμ is determined by the wavelength of the light and Γ depends on the configuration of the fiber/waveguide.
Thus, now applying Eq. 24 to the conventional fiber optic sensor considered above, with the exposed length, L being fixed at 4 cm for maximum saturation: Γ=3.1×10−3, cΔμ=2.32 cm−1 and δx=2.7ξ. Thus, if for example ξ=0.01, then the error in the saturation level is about 3%.
In the example of the inventive planar dielectric waveguide 130 of device 100 in
Thus, another aspect of the invention involves the method of first providing a waveguide comprising a planar support as a cladding on a first surface with a second surface parallel to the plane of the first surface, and terminating with a reflective surface orthogonal to the direction of propagation, then placing the second surface in contact with blood and propagating light through the waveguide toward the mirror, after which the intensity of light reflected by the mirror is measured.
Yet another important operative principle of an even more preferred embodiment of the current invention for measuring blood oxygen saturation level is to deploy a waveguide in the which the dimensions of the evanescent field is comparable to, and most preferably, much more than the dimensions of the red blood cell. It should be appreciated that if the evanescent field that interacts with the RBC is much smaller than a RBC the signal will be strongly influenced by position of a particular red blood cell relative to the waveguide. The blood component hemoglobin is concentrated within erythrocytes or red blood cells that have a torus-like shape with the diameter of each corpuscular being is about 8 μm and having a thickness of about 2 μm. Further, the evanescent field should be of a nature that allows it to also penetrate deeply into the red blood cell, that is at least a micron, or preferably at least about 2 microns, but more preferably about 4 microns. These two conditions are fulfilled for a low-dielectric-constant (low-k) planar dielectric waveguide described below.
The spatial extension of evanescent field is proportional to λ/Δn, where Δn is the difference of refractive index between core and the cladding. The refractive index of the human red blood cells is in the range 1.38-1.42 depending on concentration of the hemoglobin in it, as shown in
Thus, another embodiment of the invention is use of a dielectric material for a waveguide with refractive index lower than of silica to increase the penetration depth of the evanescent field, and thus obtain both a greater and more representative measurement of the blood oxygenation. One such preferred low-dielectric-constant material is spin-on hybrid siloxane-organic polymer, such as that known as HOSP and available from Honeywell Advanced Microelectronic Materials (Tempe, Ariz.). Thin films of HOSP could be prepared by a spin-on coating technique. The dispersion of refractive index of HOSP in wavelength range of 180 nm to 2.35 μm is shown in the
It should be appreciated from the foregoing that although a preferred form of a waveguide is a planar waveguide flush with the surface of the catheter or probe, the performance of an optical fiber (with a circular cross section, or any other non-planar waveguide form) is improved when the core refractive index is less about 1.45 at the absorption bands of Hb and HbO2
In other embodiments of the invention either the planar waveguide or a non-planar waveguide using a low refractive index core may be integrated with a catheter in signal communication with cardiac monitoring equipment, or a pacemaker or electro-cardiac defibrillator to change the pacing rate or provide a defibrillating pulse when local low blood concentrations are detected so as to prevent cardiac or other tissue ischemia.
While the invention has been described in connection with a preferred embodiment, it is not intended to limit the scope of the invention to the particular form set forth, but on the contrary, it is intended to cover such alternatives, modifications, and equivalents as may be within the spirit and scope of the invention as defined by the appended claims.
The present application claims priority to the U.S. Provisional Patent Application for a “Blood Oxygenation sensor, filed on Feb. 21, 2006, and now assigned application Ser. No. 60/775,531, which is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
60775531 | Feb 2006 | US |